Specifically, RIPK3 deficiency in an experimental model of NAFLD improved hepatic inflammation and hepatocyte injury without reducing the accumulation of fat in the liver (Afonso et al., 2021). The gene discussed is RIPK3; the disease is metabolic dysfunction-associated steatotic liver disease.